Fierce's Angus Liu speaks with Ionis CEO Brett Monia about the science behind antisense oligonucleotides, what upcoming phase 3 readouts from Ionis’ Novartis-partnered lipoprotein(a) program and AstraZeneca-partnered ATTR cardiomyopathy program could show, and how the company is working to build a commercial biotech business.